Targeted Therapies for Melanoma Brain Metastases

Anna S. Berghoff, MD, PhD
Matthias Preusser, MD*

Address
*Department of Medicine I and Comprehensive Cancer Center CNS Unit (CCC-CNS), Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
Email: matthias.preusser@meduniwien.ac.at

Published online: 3 April 2017
© The Author(s) 2017. This article is published with open access at Springerlink.com

Keywords Melanoma · Brain metastases · BRAF inhibitor · Immune checkpoint inhibitor

Opinion statement
Brain metastases are a major clinical challenge occurring in up to 60% of patients suffering from metastatic melanoma. They cause significant clinical symptoms and impair the overall survival prognosis. The introduction of targeted therapies including BRAF and MEK inhibitors as well as CTLA-4 and PD-1 axis targeting immune checkpoint inhibitors have dramatically improved the treatment and prognosis of patients with extracranial metastatic melanoma. Although, similar response rates for extra- and intracranial metastases have been reported, only few data from brain metastasis specific trials are available so far. The following review will provide an overview on the currently available data on targeted therapies, remaining questions and the most important side effects in the special clinical situation of melanoma brain metastases.

Introduction
Brain metastases (BM) are a clinical challenge in the treatment of melanoma patients. Up to 60% of patients suffering from metastatic melanoma develop this life treating and quality of life impairing complication during their course of disease [2]. Melanoma has a particularly high risk to spread to the brain compared to other frequent sources of BM like lung and breast cancer. The median survival after diagnosis of symptomatic BM traditionally ranged from 3.4 to 13.2 months [65].

New targeted treatment modalities, including BRAF and MEK inhibitors as well as immune checkpoint inhibitors, have revolutionized the treatment of metastatic melanoma patients in the last decade [40, 71]. Effective, rapid responses to BRAF inhibitors and long lasting efficacy of immune checkpoint inhibitors have entered the everyday practice. However, all data on the natural course of melanoma brain metastases remains from the era before the availability of targeted therapies. Therefore the course of disease may have significantly changed as, for example, Trastuzumab has significantly changed treatment and prognosis of metastatic breast cancer [32]. However, to this date, the incidence of BM has not decreased since the introduction of the new generation targeted
therapies in metastatic melanoma. Additionally, BM are still frequently the first site of progression, making BM treatment a particularly important aspect of melanoma therapy [17, 38]. Approximately one third of melanoma BM patients will die from BM progression, while another third dies from the combined progression of intra- and extracranial metastases [10]. Therefore, treatment strategies have to carefully address this specific progression pattern and combine effective intra- and extracranial treatment approaches.

Carefully designed trials specially concentrating on brain metastatic endpoints are therefore urgently needed. Here, especial emphasis should be given to intracranial response and the potential to prevent symptomatic brain metastases [50]. Further, brain metastasis-specific endpoints like survival without neurological deterioration should be considered and investigated in order to improve the therapy sequence for patients suffering from melanoma brain metastases [50]. A further specific challenge in the treatment of melanoma BM is the relative radio-resistance of melanoma. Therefore, systemic therapies are applied more frequently in oligo- to asymptomatic BM patients as first line treatment approach than in most other BM causing entities [1, 43]. The following review will provide an overview on the available targeted therapies in melanoma and their efficacy in the special context of BM.

### BRAF tyrosine kinase inhibitors

Activating mutations of the v-Raf murine sarcoma viral oncogene homolog B (BRAF) gene occur in up to 50% of melanoma patients, with a higher frequency among very young patients. Here, the V600E point mutation with substitution of valine to glutamate at codon 600 is the most frequently observed mutation (>80%) followed by the V600K mutation (14%) [36]. The presence of a BRAF mutation is most likely not associated with an increased risk to develop BM [36]. BRAF tyrosine kinase inhibitors like Vemurafenib and Dabrafenib effectively inhibit the downstream activated MAPK (mitogen-activated protein kinase) pathway and have shown improved disease control rates (CR + PR + SD) of up to 92%, significantly prolonged progression and overall survival compared to chemotherapy in extracranial metastatic melanoma [23, 42].

### Predictive biomarkers

The presence of the V600E and at a lesser extend the V600K BRAF mutation is highly predictive for the response to BRAF inhibitors. The most frequently occurring point mutation V600E can reliable detected with the mutation specific antibody VE1 [12]. However, DNA-based methods like gene sequencing or the COBAS test can also identify less frequently occurring point mutations. Therefore, the sequence of using immunohistochemistry (VE1 antibody) as a screening method followed by a DNA-based method in case of a negative result to rule out rare mutation types is currently proposed for routine clinical practice [51]. Importantly, the BRAF mutation presents with a high concordance between metastases from different sites if using the V600E BRAF mutation specific antibody VE1 [11, 28].

### Clinical efficacy of BRAF inhibitors in melanoma brain metastases

Initial licensing phase III trials excluded patients with active or untreated melanoma BM. However, subsequent BM specific trials have shown similar intra- and extracranial response rates for BRAF inhibitor
monotherapy. The BREAK-MB phase II study was the first to specifically address the efficacy of BRAF inhibition in patients with BRAF mutation harboring brain metastatic melanoma [34]. Overall, 172 melanoma BM patients without (n = 89; cohort A) or with (n = 83; cohort B) prior local BM treatment were included. Intra- (cohort A: 81.1%, cohort B: 89.2%) and extracranial (cohort A: 79.7%, cohort B: 83.1%) disease control rate as well as overall survival (cohort A: 33.1 weeks, cohort B: 31.4 weeks) was impressive and similar in both groups indicating that efficacy of BRAF inhibition is also given in the context of BM recurrence (Table 1). A phase II study of Vemurafenib in a cohort of patients with previously untreated (n = 90; cohort 1) and previously treated (n = 56; cohort 2) melanoma BM presented with a very similar outcome (Table 1) [41••]. Intra- (cohort 1: 18%, cohort 2: 20%) and extracranial (cohort 1: 33%, cohort 2: 23%) response rate was comparable as well as overall survival (cohort 1: 8.9 months, cohort 2: 9.6 months), although numerically less impressive compared to the responses observed for Dabrafenib.

No head to head comparisons answers the question whether to use Vemurafenib or Dabrafenib upon the occurrence of BM. Preclinical data suggest a better brain distribution of Dabrafenib [44, 63]. Currently, a clinical trial tests the accumulation nucleotide-labeled Dabrafenib in established BM as a new method to predict treatment response (NCT02700763).

Unfortunately, the response to BRAF inhibitors is limited to few months as almost all patients present with a disease recurrence within 12 months [35]. A mixed response can be frequently observed shortly before the recurrence, with still stable extracranial metastases but fast growing and multiple new BM [48]. Interestingly, the BM progression presents with a particular pattern of multiple disseminated lesions, which might reflect an invasive or migratory tumor cell phenotype [22].

## Combination of BRAF and MEK inhibitor

As outlined, although initially highly active, almost all patients developed resistance to BRAF inhibitors alone within 6–7 months most likely trough mutations resulting in MAPK reactivation [56]. In line, combination of BRAF and MEK inhibition, which inhibits the downstream activated MAPK pathways from different sites, resulted in a significantly prolonged progression free survival in extracranial metastatic melanoma [30, 33]. The MEK inhibitor trametinib is subject to P-glycoprotein efflux pumps, which has been shown to limit its efficacy in experimental BM models [68]. Interestingly, a lack of P-glycoprotein in human melanoma BM was observed, encouraging the further clinical investigation [55]. Case series suggest that the combination might also be safe and effective in BM patients, however definitive conclusion can only be drawn from the currently recruiting clinical trials (Table 2) [47•].

## Combination of BRAF inhibitors with radiotherapy

The combination of BRAF inhibitors and radiotherapy is subject to an on-going discussion. Questions including the sequencing and dosing are currently investigated in several clinical trials (Table 2). In general, melanoma is considered a radio-resistant tumor. Only small
Table 1. Selected trials on targeted therapies in melanoma brain metastases

| Study                        | Type of trial | Study population                                                                 | Targeted therapy | Intracranial disease control rate (SD + PR + CR) | Extracranial disease control rate (SD + PR + CR) | OS                                                                 |
|------------------------------|---------------|----------------------------------------------------------------------------------|------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------------------------------------------|
| BREAK-MB—Long et al.         | Phase II      | Cohort A: Newly diagnosed BM (n = 89)                                           | Dabrafenib       | BRAF V600E mutant: Cohort A: 81.1% Cohort B: 6.7% | BRAF V600E mutant: Cohort A: 79.7% Cohort B: 46.7% | BRAF V600E mutant: Cohort A: 33.1 weeks Cohort B: 16.3 weeks        |
|                              |               | Cohort B: previously treated BM (n = 83)                                        |                  | Cohort B: 89.2%                                 | Cohort B: 8.1%                                    |                                                                      |
|                              |               | Total: n = 172                                                                  |                  | Total: n = 172                                  | Total: n = 172                                    |                                                                      |
| McArthur et al.              | Phase II      | Cohort 1: Newly diagnosed BM (n = 90)                                          | Vemurafenib      | Cohort 1: 18%                                   | Cohort 1: 33%                                     | Cohort 1: 8.9 months Cohort 2: 9.6 months                           |
|                              |               | Cohort 2: previously treated BM (n = 56)                                        |                  | Cohort 2: 20%                                   | Cohort 2: 23%                                     |                                                                      |
|                              |               | Total: n = 146                                                                  |                  | Total: n = 146                                  | Total: n = 146                                    |                                                                      |
| Margolin et al.              | Phase II      | Cohort A: asymptomatic BM (n = 51)                                             | Ipilimumab       | Cohort A: 25%                                   | Cohort A: 33%                                     | Cohort A: 7 months Cohort B: 3.7 months                             |
|                              |               | Cohort B: symptomatic BM (n = 21)                                               |                  | Cohort B: 10%                                   | Cohort B: 10%                                     |                                                                      |
| Goldberg et al.              | Phase II      | Untreated melanoma (n = 18) or non-small cell lung cancer BM                     | Pembrolizumab    | Melanoma cohort (n = 18): 42%                   | Melanoma cohort (n = 18): 50%                     | Melanoma cohort (n = 18): median OS not reached after median follow-up of 11.6 months |

retrospective case series postulate an increased response rate by the combination of Vemurafenib and radiotherapy. This is further supported by preclinical findings suggesting a radio-sensitizing effect of Vemurafenib [45, 61]. On the other hand, increased side effects such as
skin symptoms have been reported for the combination, thus potentially limiting the clinical applicability [1, 29]. Based on these data, BRAF inhibitors should probably be paused during the radiotherapy.

| Study | Type of trial | Targeted therapy | Combination with radiotherapy | Intervention | Primary endpoint |
|-------|---------------|------------------|-----------------------------|-------------|-----------------|
| BRAF and MEK inhibitor therapy | NCT02537600 Phase II | Vemurafenib + combretinib | None | Combination of vemurafenib + combretinib in symptomatic and asymptomatic BM patients | Intracranial response rate |
| | NCT02974803 Phase II | Dabrafenib + trametinib | Stereotactic radiosurgery | Concurrent dabrafenib + trametinib with stereotactic radiosurgery in active BM | Intracranial objective response rate |
| Immune checkpoint inhibitor monotherapy | NCT02085070 Phase II | Pembrolizumab | None | Pembrolizumab monotherapy in symptomatic patients | Objective response rate |
| | NCT02621515 Phase II | Nivolumab | None | Nivolumab monotherapy in BM patients without or stable steroid dosage | Intracranial best overall response |
| Combination of two immune checkpoint inhibitors | NCT02374242 Phase II | Ipilimumab + nivolumab | None | Nivolumab vs. nivolumab + ipilimumab in patients with asymptomatic BM | Intracranial response rate |
| | NCT02460068 Phase III | Ipilimumab + nivolumab | None | Fotemustine + ipilimumab vs. Ipilimumab + nivolumab vs. fotemustine alone in patients with asymptomatic BM | Overall survival |
| | NCT02320058 Phase II | Ipilimumab + nivolumab | None | Ipilimumab + nivolumab followed by nivolumab monotherapy in patients with asymptomatic BM | Clinical benefit rate |
| Combination of immune checkpoint inhibitor with radiotherapy | NCT02097732 Phase II | Ipilimumab | Stereotactic radiosurgery | Ipilimumab induction flowed by stereotactic radiosurgery and ipilimumab in patients with oligo- to asymptomatic BM | Local control rate |
| | NCT02115139 Phase II | Ipilimumab | Stereotactic radiosurgery | Combination of ipilimumab and stereotactic radiosurgery in newly diagnosed BM patients | 1 year survival rate |
| | NCT02858869 Pilot | Pembrolizumab | Stereotactic radiosurgery | Combination of pembrolizumab and stereotactic radiosurgery | Proportion of dose limiting toxicities |
| | NCT02716948 Pilot | Nivolumab | Stereotactic radiosurgery | Combination of nivolumab and stereotactic radiosurgery | Incidence of serious adverse events |
| New therapy approaches | NCT02881549 Phase II | Pembrolizumab + bevacizumab | None (prior radiotherapy at most 14 days before treatment allowed) | Combination of pembrolizumab + bevacizumab | Brain metastasis response rate |
| | NCT02452294 Phase II | Buparlisib (PI3K Inhibitor) | None | Buparlisib monotherapy in patients with BM not eligible for radiotherapy or surgery | Intracranial disease control rate |
| | NCT01904123 Phase I | WP1066 (STAT3 inhibitor) | None | WP1066 monotherapy | Maximum tolerated dose |
| | NCT02308020 Phase II | Abemaciclib (CDK inhibitor) | None | Abemaciclib in patients without or stable steroid dosage | Percentage of participants achieving complete response |
Side effects of BRAF inhibitors in brain metastasis patients

Classical side effects of BRAF inhibitors include gastrointestinal symptoms (diarrhea, nausea, vomiting), skin symptoms (cutaneous squamous cell carcinoma, keratoacanthoma, photosensitivity reaction, hyperkeratosis, rash), fatigue, pyrexia, and elevated liver enzymes [23, 42]. Frequency of cutaneous squamous cell carcinoma and keratoacanthoma is lower in patients treated with the combination of BRAF and MEK inhibitor [30]. No additional and particular no increase in neurological side effects were observed in BM patients, showing that BRAF inhibitors are safe in this particular population [34, 41].

Immune checkpoint inhibitors

Immune checkpoint inhibitors have dramatically changed the treatment of metastatic melanoma with a substantial overall survival improvement [24, 57–59]. So far, CTLA4 (cytotoxic T-lymphocyte protein 4; Ipilimumab) and PD-1 (programmed death 1; Nivolumab, Pembrolizumab) axis targeting immune checkpoint inhibitors have been approved for the treatment of metastatic melanoma. The anti-tumor effect is mediated by T cells as immune checkpoint inhibitors increase the tumor-specific T cell response [40]. Response assessment might be challenging as pseudoprogression caused by the initial influx of immune cell in the tumor tissue can mimic disease progression but may result in subsequent disease control [72]. Importantly, response patterns to immune checkpoint inhibitors may differ from traditional chemotherapy and other targeted therapies. The period to best response can be longer than with targeted therapies or chemotherapy. Some patients present initially with a stabilization of the disease and delayed tumor shrinkage only after several weeks or months of treatment. The resulting responses may however be long lasting and some patients present with disease stabilization for prolong periods [24, 57, 58]. Long-term follow-up of patients treated in phase II and III trials with ipilimumab reveals a survival plateau of 20% starting from 3 years and extending up to 10 years [62]. The response to PD-1 axis targeting checkpoint inhibitors or the combination of both have shown even more profound responses than Ipilimumab monotherapy, and the long-term follow-up indicates an even higher survival plateau [57, 58].

Predictive biomarkers

Several potential predictive biomarkers have been postulated for the response to immune checkpoint inhibitors [18]. For ipilimumab, some histological characteristics like high density of tumor infiltrating lymphocytes as well as genetic characteristics including a neo-antigen signature and high mutational load were postulated to have a predictive potential [20, 64, 69]. Expression of PD-L1 on the tumor cells is a promising predictive biomarker for the response to PD-1 axis targeting immune checkpoint inhibitors. However, the negative predictive value of PD-L1 expression is low, as responses were also observed in a significant fraction of patients without PD-L1 expression [67]. Here, several different antibodies and cut off values were postulated. The probability of response increases with the percentage of PD-L1 expressing cells, with the highest probability in patients with >50% of tumor cells presenting with expression [60, 70, 73]. A high density of tumor infiltrating lymphocytes as well
as a similar frequency of PD-L1 expression as compared with extracranial tumor sites has been reported for melanoma BM [7].

**Clinical efficacy of immune checkpoint inhibitors in melanoma brain metastases**

It has been of dispute whether immune checkpoint inhibitors can reveal their full therapeutic potential in BM, as these monoclonal antibodies with a large molecular weight are unable to cross the blood brain barrier [8, 9]. However, the mode of action of immunotherapies has to be taken into account, as the T cell priming influenced by immune checkpoint inhibitors may to some extent occur in immunological sites distant from the tumor (e.g., regional lymph nodes). T cells activated in such sites may cross an intact blood brain barrier [52]. Further, the blood brain barrier is disrupted in contrast enhancing BM. Consequently, anti-PD-1 immune checkpoint inhibitors may be able to enter and inhibit the binding of PD-L1 (programmed cell death ligand 1) on tumor cells and the PD-1 receptor on T cells in at least some areas of BM. In line with these considerations, clinical activity of immune checkpoint inhibitor monotherapy was observed in melanoma BM patients. A phase II study on ipilimumab monotherapy in patients with melanoma BM included overall 72 patients in two cohorts. Cohort A \((n = 51)\) included asymptomatic patients without corticosteroid treatment and cohort B \((n = 21)\) patients with symptoms requiring corticosteroid treatment [39]. Intra- (cohort A: 25%, cohort B: 10%) and extracranial (cohort A: 33%, cohort B: 10%) disease control rate applying adapted response criteria was similar, although a difference was observed between the asymptomatic patients (cohort A) and the symptomatic ones (cohort B). Therefore, corticosteroid treatment might impact the efficacy of ipilimumab therapy either due to the resulting immune suppression or due to the impaired clinical condition of the patients, which is resembled by the need for corticosteroid treatment. Here, data from extracranial metastatic melanoma indicates that corticosteroid treatment for the control of immune related side effects does not alter response probability [21, 25]. In symptomatic BM patients in need for steroid treatment, the disease progression may be too fast to allow enough time for the immune checkpoint inhibitor to develop its full antitumor activity. As PD-1 axis targeting immune checkpoint inhibitors have shown higher response rates in extracranial melanoma, these might also be the more promising agents for melanoma BM patients. So far, however, only little data on the intracranial efficacy of anti-PD-1 immune checkpoint inhibitor monotherapy exists. A phase II trial on pembrolizumab monotherapy in BM patients included different primary histologies including melanoma \((n = 18)\) and non-small cell lung cancer \((n = 18)\) [19••]. Unfortunately, not all melanoma patients were eligible for response assessment, however 4/14 (28%) patients presented with confirmed intracranial partial response and 2/14 (14%) with stable intracranial disease, resulting in a 42% intracranial disease control rate. Extracranial disease control was 50%, with 4/16 (25%) patients presenting with extracranial partial or complete response and 4/16 (25%) with stable disease. Conclusions have to be drawn with caution due to the limited number of included patients. Nonetheless, observed response rates are promising and currently recruiting trials are further addressing the efficacy of pembrolizumab in patients with melanoma BM (Table 2). No results from BM specific clinical trials, investigating the efficacy of nivolumab treatment in melanoma BM
patients, are yet available. However, several case series indicate the safety and efficacy of nivolumab monotherapy [6, 37]. The currently recruiting clinical trials will provide a deeper and more profound insight in the value of immune checkpoint inhibitor therapy in melanoma BM patients (Table 2).

**Combination of immune checkpoint inhibitors with radiotherapy**

Combination of radiotherapy and immune checkpoint inhibitors has shown to increase response also in not initially radiated lesion due to the so-called abscopal effect [49, 66]. In theory, antigen release due to cell death caused by the radiation increases the T cell mediated immune response facilitated by the immune checkpoint inhibitor treatment. Therefore, several case series postulate an increased response rate through the combination and sequencing of immune checkpoint inhibitors and stereotactic radiotherapy [16, 26, 53]. However, definitive conclusions cannot be drawn yet but currently recruiting clinical trials addressing this question in melanoma BM patients will provide further insights (Table 2).

**Combination of immune checkpoint inhibitor and chemotherapy**

As previously addressed for the combination with radiotherapy, the combination with chemotherapy is also postulated to increase antigen release and thereby potentiate the efficacy of the immune checkpoint inhibitor therapy. A phase II clinical trial focused on the combination of fotemustine and ipilimumab and included a subcohort of BM patients (n = 20). Again a cohort included patients with previous radiotherapy (n = 7) and a treatment naïve cohort with asymptomatic BM (n = 13). Here, 10/20 (50%) patients achieved intracranial disease control (SD + PR + CR) [15]. As a consequence, the applied combination of fotemustine and ipilimumab is currently studied in subsequent clinical trials (Table 2).

**Combination of two immune checkpoint inhibitors**

Combination approaches of ipilimumab and nivolumab were shown to result in significantly improved progression-free survival in patients with metastatic melanoma [31]. However, treatment-related adverse events also increased in the combination arm with grade 3 and 4 events occurring in up to 55% of patients. A small case series of nine patients (6/9 with BM) populates safety of the combination of low dose ipilimumab (1 mg/kg) with pembrolizumab in BM patients as no increase in neurological side effects was observed [27]. Again, several on-going clinical trials are currently addressing this promising combination (Table 2).

**Combination of BRAF inhibitor and immune checkpoint inhibitor**

Combination of a BRAF inhibitor, producing fast effective tumor shrinkage, and an immune checkpoint inhibitor with slowly occurring but potentially long-lasting response would be tempting. Unfortunately, initial safety data revealed a marked liver toxicity of the combination [54]. Sequencing with induction of the BRAF inhibitor and switch to the immune checkpoint inhibitor after few weeks might be an interesting strategy, which is currently subject to clinical trials (Table 2) [3].

**Side effects in brain metastasis patients**

PD-1 axis targeting immune checkpoint inhibitors are generally better tolerated compared to CILTA-4 immune checkpoint inhibitors [58]. The side effects are
mostly caused by the increased immune response and encompass several auto-
immune mediated side effects. Most frequent adverse events in patients treated
with PD-1 axis targeting immune checkpoint inhibitors are colitis, pneumonitis,
skin reactions, and endocrine (thyroiditis, hypophysitis) adverse events [57, 58].
Similarly, diarrhea, rash, puritus, liver enzyme increase, and endocrine
(thyroiditis, hypophysitis) adverse events are the most common one in
ipilimumab-based treatment [24]. The side effect profile among BM patients
presented to be not significantly different compared to patients without brain
metastases, especially no particular increase in neurological side effects was ob-
served [19••, 39]. Pseudoprogression with resulting symptoms due to the volume
increase was occasionally reported for BM patients, especially for the combination
of immune checkpoint inhibitors and stereotactic radiosurgery [14, 26•].

Conclusions

The development of several new systemic treatment options including, BRAF
and MEK as well as CTLA-4 and PD-1 targeting immune checkpoint inhibitors
have revolutionized the daily practice of melanoma treatment [40]. Early BM-
specific clinical studies have postulated comparable intra- and extracranial
response rates for this new generation of targeted therapies [19••, 34, 39, 42].
Although encouraging, several important questions on the combination, the
sequencing or the concomitant application of radiotherapy remain unan-
swered. The currently recruiting BM-specific trials are likely to answer some of
these questions and give a further direction for the optimal treatment combi-
nation in melanoma BM patients (Table 2). Further, the next generation of
targeted and immune therapies is in the pipeline. Here, PI3K or CDK inhibition
might be promising as well as immune modulating therapies targeting e.g., PD-
L1, Lag3 or Tim3 [4, 5, 13, 46]. In conclusion, targeted therapies including BRAF
inhibitors and immune checkpoint inhibitors have become an important
backbone in the treatment of melanoma BM and the on-going clinical trials will
further redefine the clinical practice in this particular patient cohort.

Acknowledgements

Open access funding provided by Medical University of Vienna.

Compliance with Ethical Standards

Conflict of Interest
Anna Sophie Berghoff has received travel support from Roche and BMS, as well as honoraria from Roche.
Matthias Preusser has received research support from Böhringer-Ingelheim, GlaxoSmithKline, Merck Sharp &
Dohme and Roche and honoraria for lectures, consultation or advisory board participation from Bristol-Myers
Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche and
Astra Zeneca.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as:
• Of importance
•• Of major importance

1. Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S. Evolving treatment options for melanoma brain metastases. Lancet Oncol. 2015;16(13):E486–497. doi:10.1016/S1470-2045(15)00141-2.
2. Amer MH, Al-Sarraf M, Baker LH, Vaitkovicus VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42(2):660–8.
3. Amin A, Lawson DH, Salama AK, Koon HB, Guthrie Jr T, Thomas SS, et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated bBRAF-mutated metastatic melanoma. J Immunother Cancer. 2016;4:44. doi:10.1186/S40425-016-0148-7.
4. Atefi MS, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, et al. Effects of MAPK and PI3k pathways on PD-L1 expression in melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(21):5537–46. doi:10.1158/1078-0432.Ccr-13-3003.
5. Baksh K, Weber J. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. Semin Oncol. 2015;42(3):363–77. doi:10.1053/J.Seminoncol.2013.02.015.
6. Basnet A, Saad N, Benjamin S. A case of vanishing brain metastasis in a melanoma patient on nivolumab. Anticancer Res. 2016;36(9):4795–8. doi:10.21873/Anticanres.11038.
7. Berghoff AS, Ricken G, Widschalm G, Rajky O, Dieckmann K, Bimer P, et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology. 2014. doi:10.1111/His.12537.
8. Berghoff AS, Preuress M. The inflammatory microenvironment in brain metastases: potential treatment target? Chin Clin Oncol. 2015;4(2):21. doi:10.3978/j.issn.2304-3865.2015.06.03.
9. Berghoff AS, Venur VA, Preuss M, Ahluwalia MS. Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am Soc Clin Oncol Educ Book / Asco Am Soc Clin Oncol Meet. 2016;35:E116–122. doi:10.14694/Edbk_100005.
10. Berghoff AS, Schur S, Fureder LM, Gatterbauer B, Dieckmann K, Widhalm G, et al. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open. 2016;1(2):E000024. doi:10.1136/ESmoopen-2015-000024.
11. Capper D, Berghoff AS, Magele M, Ilhan A, Wohrer A, Hacld M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012;123(2):223–33. doi:10.1007/S00401-011-0887-Y.
12. Capper D, Preuss M, Habel A, Sahn F, Ackermann U, Schindler G, et al. Assessment of braf V600e mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122(1):11–9. doi:10.1007/S00401-011-0841-Z.
13. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, et al. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(21):5537–46. doi:10.1158/1078-0432.Ccr-13-3003.
14. Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, Goldberg SB, Mahajan A, et al. Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunol Res. 2016;4(3):179–82. doi:10.1158/2326-6066.Cir-15-0160.
15. Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Franceschini D, Franzese C, Navarria P, Ascolese AM, De Rose F, Del Vecchio M, et al. Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases? Cancer Treat Rev. 2016;50:1–8. doi:10.1016/J.Ctrv.2016.08.003.

Frenard C, Peuvrel L, Jean MS, Brocard A, Knol AC, Gibney GT, Weiner LM, Atkins MB. Predictive bio-

Harmankaya K, Erasim C, Koelblinger C, Ibrahim R, Hamid O, Schmidt H, Hassan J, et al. The association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204. doi:10.1186/1479-5876-9-204.

Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976–83. doi:10.1016/S1470-2045(16)30053-5.

First phase II study on pembrolizumab monotherapy in patients with brain metastases either from non-small cell lung cancer or melanoma.

Hamid O, Schmidt H, Nissab A, Ridolfi L, Aamdal S, Lin NU, Winer EP. Brain metastases: the Her2 paradigm. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(6):1648–55. doi:10.1158/1078-0432.Ccr-06-478.

Haueis SA, Kranzlin P, Manganag J, Cheng PF, Urosevic-Maivald M, Braun RP, et al. Does the distribution pattern of brain metastases during braf inhibitor therapy reflect phenotype switching? Melanoma Res. 2017. doi:10.1097/Cmr.0000000000000338.

Harmsnayka K, Erasim C, Koolblinger C, Ibrahim R, Hoos A, Pehamberger H, et al. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol. 2011;28(4):1140–4. doi:10.1007/S12032-010-9606-0.

Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65. doi:10.1016/S0140-6736(12)60868-X.

Horvat TZ, Adel NG, Dang TO, Montaz P, Postow MA, Callahan MK, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193–8. doi:10.1200/Jco.2015.60.8448.

Clinical study on the combination of ipilimumab and stereotactic radiosurgery in patients with melanoma brain metastases.

Kirberger MC, Hauschild A, Schuler G, Heinzerling L, Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma. Eur J Cancer. 2016;65:182–4. doi:10.1016/J.Ejca.2016.07.003.

Kroezes SG, Fritz C, Hoyer M, Lo SS, Ricardi U, Sahgal A, et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev. 2016;53:23–37. doi:10.1016/J.Crrev.2016.11.013.

Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in braf-mutated melanoma. N Engl J Med. 2014;371(20):1867–76. doi:10.1056/Nejmoa1408868.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey C, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/Nejmoa1504030.

Lin NU, Winer EP. Brain metastases: the Her2 paradigm. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(6):1648–55. doi:10.1158/1078-0432.Ccr-06-2478.

Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol. 2016;34(8):871–8. doi:10.1200/Jco.2015.62.9345.

Long GV, Trefzer U, Davies MA, Keeford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (Break-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087–95. doi:10.1016/S1470-2045(12)70431-X.

Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a
pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016;17(12):1743–54. doi:10.1016/S1470-2045(16)30578-2.

36. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239–46. doi:10.1200/Jco.2010.32.4327.

37. Luttmann N, Gratz V, Haase O, Eckey T, Langan EA, Zillikens D, et al. Rapid remission of symptomatic brain metastases in melanoma by programmed-death-receptor-1 inhibition. Melanoma Res. 2016;26(5):528–31. doi:10.1097/Cmr.0000000000000270.

38. Ma MW, Qian M, Lackey DJ, Berman RS, Shapiro RL, Pavlick AC, et al. Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site. Neuro Oncol. 2012;14(7):849–58. doi:10.1093/Neuonc/Nos113.

39. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459–65. doi:10.1016/S1470-2045(12)70090-6.

40. Margolin K. The promise of molecularly targeted and immunotherapy for advanced melanoma. Curr Treat Options Oncol. 2016;17(9):48. doi:10.1007/S11864-016-0421-5.

41. McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2. Multicentre Stud Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2016. doi:10.1093/Annonc/Mdw641.

42. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dunnger R, et al. Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–32. doi:10.1016/S1470-2045(14)70012-9.

43. Migliorini D, Fertani S, Dietrich PY. Upfront targeted therapy for symptomatic melanoma brain metastases: paradigm changing? CNS Oncol. 2016;5(4):199–201. doi:10.2217/Cns-2016-0019.

44. Mittapalli RK, Vaidhyaanathan S, Dudek AZ, Elmqist WF. Mechanisms limiting distribution of the threonine-protein kinase B-Raf(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013;344(3):655–64. doi:10.1124/jpet.112.201475.

45. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol. 2013;113(3):411–6. doi:10.1007/S11060-013-1127-1.

46. Niessner H, Schmitz J, Tabatabai G, Schmid AM, Calaminus G, Sinnberg T, et al. PI3k pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22(23):5818–28. doi:10.1158/1078-0432.Ccr-16-0064.

47. Patel BG, Ahmed KA, Johnstone PA, Yu HH, Etame AB. Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma Res. 2016;26(4):382–6. doi:10.1097/Cmr.0000000000000250.

Case series on the combination of BRAF and MEK inhibition with radiosurgery in patients with melanoma brain metastases.

48. Peve reel L, Saint-Jean M, Quereux G, Brocard A, Khammari A, Knol AC, et al. Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib. J Neurooncol. 2014;120(1):147–54. doi:10.1007/S11060-014-1533-Z.

49. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–31. doi:10.1056/Nejmoa1112824.

50. Preusser M, Winker F, Collette L, Haller S, Marreaud S, Soffietti R, et al. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. Eur J Cancer. 2012;48(18):3439–47. doi:10.1016/j.ejca.2012.07.002.

51. Preusser M, Capper D, Hartmann C, Euro CNSRC. IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clin Neuropathol. 2011;30(5):217–30.

52. Preusser M, Berghoff AS, Thallinger C, Zielinski CC. Cancer immune cycle: a video introduction to the interaction between cancer and the immune system. ESMO Open. 2016;1(1):E000056. doi:10.1136/Esmoopen-2016-000056.

53. Qian JM, Yu JB, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368(14):1365–6. doi:10.1056/Nejmoa1302338.

54. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Cancer immune cycle: a video introduction to the interaction between cancer and the immune system. ESMO Open. 2016;1(1):E000056. doi:10.1136/Esmoopen-2016-000056.

55. Richtig E, Asslaber M, Partl R, Avian A, Berghold A, Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res Off J Am Assoc Cancer Res.
57. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30. doi:10.1056/Nejmoa1412082.

58. Robert C, Schachtier J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. doi:10.1056/Nejmoa1503093.

59. Robert C, Thomas L, Bondarenko I, O’day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26. doi:10.1056/Nejmoa1104621.

60. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17. doi:10.1016/S0140-6736(14)60958-2.

61. Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields J. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol. 2011;98(3):394–9. doi:10.1016/j.radonc.2010.12.017.

62. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–94. doi:10.1200/Jco.2014.36.0276.

63. Seifert H, Hirata E, Gore M, Khabra K, Messiou C, Larkin J, et al. Extrinsic factors can mediate resistance to braf inhibition in central nervous system melanoma metastases. Pigment Cell Melanoma Res. 2016;29(1):92–100. doi:10.1111/Pcmr.12424.

64. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–99. doi:10.1056/Nejmoa1406498.

65. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2011. doi:10.1200/Jco.2011.38.0527.

66. Stamell EF, Wolchok JD, Gnajatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys. 2013;85(2):293–5. doi:10.1016/j.ijrobp.2012.03.017.

67. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. doi:10.1056/Nejmoa1200690.

68. Vaidyanathan S, Mitatapalli RK, Sarkaria JN, Elmquist WF. Factors influencing the CNS distribution of a novel MEK-1/2 Inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metab Dispos. 2014;42(8):1292–300. doi:10.1124/Dmd.114.058339.

69. Van Allen E, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207–11. doi:10.1126/Science.Aad0095.

70. Weber JS, Yu B, Kudchadkar RR, Gallenstein D, Ce H, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311–8. doi:10.1200/Jco.2013.51.4802.

71. Wolchok J. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2012;23 Suppl 8:Viii15–21. doi:10.1093/anncard/Mds258.

72. Wolchok JD, Hoos A, O’day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(23):7412–20. doi:10.1158/1078-0432.Ccr-09-1624.

73. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33. doi:10.1056/Nejmoa1302369.